articleThe Lancet OncologyJun 4, 2016GREEN OA

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

SBSarah B. GoldbergSGScott GettingerAMAmit MahajanACAnne C. ChiangRSRoy S. Herbst

Yale Cancer Center · Yale University · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

994
total citations
FWCI
67.75
Percentile
100%
References
35
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Medicine
  • Pembrolizumab
  • Brain metastasis
  • Melanoma
  • Internal medicine
  • Oncology
  • Lung cancer
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding